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Background: Cancer antigen 125 (CA125) is made by peritoneal mesothelial cells and can be measured in spent
dialysate effluent from peritoneal dialysis (PD) patients. It has been suggested that CA125 is a marker of peritoneal
mesothelial cell mass and turnover. As PD CA125 increases during peritoneal inflammation, we wished to
determine whether measuring PD CA125 during peritonitis provided additional information in determining
outcome of peritonitis.
Methods: We prospectively measured peritoneal CA125 in 127 adult PD patients presenting with 187 acute
episodes of PD peritonitis, measuring peritoneal CA125 from a sample of dialysate effluent obtained from a
4 hour 2 litre 13.6 g/l dextrose peritoneal dwell.
Results: Mean patient age 60.8 ± 17.1 years, 62.6% male, 33.7% diabetic and the median PD vintage was 22
(11-48) months. 127 patients (66.8%) presented with their first episode of peritonitis, 20% their second episode,
13.2% third or greater. Gram positive bacteria accounted for 64.7% of all peritonitis episodes and Gram negative
bacteria 21.1%. Treatment was successful for 151 episodes of PD peritonitis (81.1%). The median PD effluent
total WBC was 1240 (430-3660) /ml and serum CRP 67 (20-144) mg/l, with a PD CA125 of 38 (20.3-72.3) IU/l
on presentation. There were positive correlations between PD effluent CA125 concentrations and total WBC on
presentation (r = 0.41, p = <0.001) and dialysis vintage (r = -0.43, p < 0.001) but not with patient age, diabetic status,
or serum CRP.
There was no difference in PD effluent CA125 concentrations between Gram positive, and Gram negative peritonitis or
between those episodes which responded to treatment, median 38 IU/ml (21-69) vs those with treatment failures 38
IU/ml (15-94).
Conclusion: We did not find any additional diagnostic or prognostic benefit for measuring effluent CA125 in PD patients
presenting with acute peritonitis compared to standard investigations, including peritoneal WBC and serum CRP. As such
our study would not support the routine measurement of peritoneal CA125 during episodes of peritonitis.
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Cancer antigen 125 (CA125) is a glycoprotein that has
been widely used to screen for ovarian cancer. Subse-
quently, human mesothelial cells were also demonstrated
to secrete CA125, and CA125 has been proposed to re-
flect mesothelial cell mass in stable peritoneal dialysis
(PD) patients [1], and this led to the growing popularity* Correspondence: andrewdavenport@nhs.net
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article, unless otherwise stated.of measuring CA125 as a surrogate biomarker of mesothe-
lial cell mass, peritoneal function and peritoneal membrane
preservation [2-4]. However it was soon recognised that
peritoneal dialysate effluent CA125 concentrations decline
with time on PD and also with encapsulating peritoneal
sclerosis [4,5], and yet on the other hand intra-peritoneal
inflammation can lead to an increase in peritoneal CA125
[6]. Indeed it was suggested that peritoneal CA125 could be
used to monitor the effects of inflammation with the peri-
toneum, as after increasing concentrations then fell withoMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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the most common cause of PD technique failure [7,8], and
although reports have claimed that the initial peritoneal di-
alysate effluent white cell count can predict which episodes
will respond to appropriate treatment [9], other studies
have suggested that the day 3 peritoneal dialysate effluent
cell count has greater predictive value [10], whereas others
have reported no association between illness severity scores,
including peritoneal white cell counts and micro-organism
were not predictive of subsequent outcomes [11]. As such
we decided to assess the possible diagnostic yield and prog-
nostic value of peritoneal dialysate effluent CA125measure-
ments in cases of acute PD peritonitis.
Methods
We prospectively measured peritoneal CA125 as we
had hypothesised that peritoneal dialysate effluent con-
centrations may reflect the severity of intraperitoneal
inflammation and predict modality outcomes [12,13].
CA125 was measured using a sandwich immunoassay
with chemi-luminescence detection (Roche Diagnos-
tics Modular Analytics E170 analyser) in 127 adult PD
patients under the care of a university teaching hos-
pital presenting with 187 acute episodes of acute PD
peritonitis between 2005 and 2013. PD peritonitis was
defined as > 100 WBC/ml with > 50% polymorpho-
nuclear cells recovered from a standard 2 litre 13.6 g/l
dextrose peritoneal dialysate instilled for a 4 hour
dwell in PD patients presenting with a cloudy PD efflu-
ent, and or signs and symptoms of abdominal pain.
Corresponding 30-50 ml peritoneal dialysate effluent
samples were also taken for standard microscopy and
microbacteriology laboratory cultures and in addition
peritoneal dialysate effluent was also inoculated into
BD Bactec™ Plus Aerobic/F and Plus Anaerobic/F
Mediumand Bactec™ automated microbiology growth
and detection system (Beckton Dickson and Company,Figure 1 Correlation between log total peritoneal dialysate
effluent white cell count (cells/ul) and CA-125. Both log values to
base 10, Spearman correlation r = 0.41 p <0.001.Plymouth, UK). Peritoneal dialysate effluents were also
sent for cytospin analysis with cell staining to confirm
both acute inflammatory changes and cell types. A
sample of the peritoneal dialysate effluent from the
4 hour 13.6 g/l dextrose dwell was taken for peritoneal
CA125 measurement. Serum CA125 was measured
using the same immunoassay as for peritoneal CA125,
and serum C reactive protein (CRP) by the same
method as the UK National Amyloid Centre.
Approvals
This retrospective audit complied with both the local
Royal Free Hospital Research and Development office
and the UK NHS guidelines for clinical audit and ser-
vice development, available at http://www.hra.nhs.uk/
documents/2013/09/defining-research.pdf, and http://
www.gov.uk/government/publications/health-research-
ethics-committees-governance-arrangements.
Statistical analysis
Data is presented as mean ± standard deviation, or me-
dian and interquartile range, unless otherwise stated.
Statistical analysis used SPSS version 20 (SPSS, Univ
Chicago, USA) and Prism version 6.0 (GraphPad, San
Diego, USA) employing student’s t test and Man
Whitney U test, Spearman’s correlation, and anova
using Kruskal Wallis test with post hoc analysis where
appropriate. Multiple linear correlation analysis was
performed to determine which variables were associ-
ated with PD CA125, with nonparametric variables log
transformed, then using a step backwards model, ini-
tially including all variables with p < 0.1 on simple cor-
relation, and then eliminating variables that were not
significant, or had 95% confidence limits crossing the
line of unity unless they did not increase the statistical
fit of the model. Receiver operator curves were used to
analyse the effect of PD CA125 on technique survival.
Statistical analysis was taken at p <0.05.
Results
The mean age of patients presenting with PD peritonitis
was 60.8 ± 17.1 years (range 20-92 years), 62.6% male,
33.7% diabetic and median PD vintage was 22 (11-48)
months. 127 patients (66.8%) presented with their first
episode of peritonitis, 20% their second episode, 6.8%
their third, 3.2% their fourth, and 3.2% with their fifth or
greater. Gram positive bacteria accounted for 64.7%
(123) of all peritonitis episodes, Gram negative bacteria
21.1% (40), culture negative peritonitis (CNS) 9.5%, fun-
gal peritonitis 2.6% and mixed organism peritonitis in
2.1%. Treatment was successful for 151 episodes of PD
peritonitis (81.1%), with treatment failures (catheter re-
moval, recurrence, relapse, or death) in 36 patients
(18.9%). Five patients (2.6%) died.
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3660)/ml on presentation and 37 (11.3-91)/ml by day 3.
The serum CRP on presentation was 67 (20-144) mg/l,
and 58 (22-148) mg/l on day 3, with a maximum CRP of
131 (46-236) mg/l. The median peritoneal dialysate
CA125 on presentation was 38 (20.3-72.3) U/l with a
serum CA125 15 (11-26) U/l, giving a ratio or periton-
eal/serum CA125 of 1.85 (1.1-3.2).
There were positive correlations between peritoneal
dialysate effluent CA125 concentrations and total
white cell count on presentation (r = 0.41, p = <0.001)
(Figure 1), and also with the day 3 peritoneal dialysate
total WBC (r = 0.37, p < 0.001). Peritoneal CA125 also
had simple correlations to both dialysis vintage (r = -0.43,
p < 0.001) and serum CA125 (r = 0.59, p = 0.001) but not
with patient age, diabetic status, serum CRP on presenta-
tion, day 3 or maximum CRP. On multiple linear correl-
ation peritoneal dialysate effluent CA125 correlated with
both dialysis vintage (β coefficient -0.27, 95% confi-
dence limits -0.394 to -0.148, standard error 0.057,
t statistic -4.36, p < 0.001) and PD effluent total white
blood cell count (β coefficient 0.221, 95% confidence
limits 0.13 to 0.312, standard error 0.046, t statistic -4.79,
p < 0.001), r2 for model 0.23, and adjusted r20.22.
There was no difference in PD effluent CA125 concen-
trations between Gram positive, Gram negative and
culture negative peritonitis (Figure 2). There was a non-
significant trend for PD effluent CA125 to decline withFigure 2 Box and whisker plot of median, interquartile and 95% conf
presentation of PD peritonitis according to underlying bacterial infecincreasing number of peritonitis episode (Figure 3).
There was no difference in PD effluent CA125 concen-
trations between those episodes which responded to
treatment, median 38 IU/ml (21-69) vs those who suf-
fered treatment failures, 38 IU/ml (15-94) (Table 1).
Similarly CA-125 peritoneal dialysis effluent concentra-
tions on presentation did not predict short or longer
term PD survival (p = 0.847, r = .-0.014, and p = 0.835,
r = -0.015 respectively), nor did the ratio of peritoneal to
serum CA125 (p = 0.249, r = 0.132 and p = 0.29, r = 0.120
respectively).
A receiver operator curve (ROC) analysis performed
to determine whether PD effluent CA125 had any deter-
mining effect on peritoneal dialysis technique survival.
In neither case was PD CA125 found to have any signifi-
cant impact for either early or late peritoneal dialysis
technique survival (p = 0.87, p = 0.71 respectively), and
ROC area 0.52, p = 0.707.
Discussion
Characterisation of human peritoneal mesothelial cells
shows that these mesenchymal cells [14] can produce
CA125 [15]. In keeping with earlier smaller studies, peri-
toneal dialysate effluent CA125 was increased when PD
patients presented with acute episodes of PD peritonitis
[6]. In our study there was a correlation between effluent
CA125 and total white cell counts, suggesting that the
increased CA125 may reflect local intra-peritonealidence limits of peritoneal dialysate CA125 effluents measured on
tion. P > 0.05by Kruskal Wallis anova.
Figure 3 Box and whisker plot of median, interquartile and 95% confidence limits of peritoneal dialysate CA125 effluents measured
on presentation of PD peritonitis according to whether patients experienced 1st, 2nd , 3rd, 4th, 5th or greater number of peritonitis
episode. P for trend >0.05.
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over [6], but not systemic inflammation as there was
no correlation with serum CRP. Although there were
statistically significant correlations between peritoneal
dialysate effluent CA125 and WBC, the r2 values were
somewhat low, as such only 13.7-16.8% of the variance
in peritoneal dialysate effluent CA125 concentrations
could be explained by WBC, so conversely 83.2-86.3%
of the explanation lies elsewhere than effluent WBC.
Other reports observed a reduction in PD effluent
CA125 with dialysis vintage in stable PD patients [4],
we also found that PD effluent CA125 was lower in
patients with longer peritoneal dialysis vintage duringTable 1 peritoneal dialysis CA125 concentrations (IU/L) from
exchange and outcomes assessed as whether patients remain
or transferred to hemodialysis (PD-)
Organisms 3 months PD+ 3 mont
Gram + ve 37 (23-68) 30 (9-8
Gram -ve 54 (22-75) 49 (33-
Culture negative 25 (16-44) 57 (14-
Fungal - 35 (18-
Polymicrobial 28 (25-31) 135 (2-
Patients were censored at time of transplantation. Data expressed as median (in
No statistical differences.PD peritonitis. Although cell culture studies have re-
ported that donor age of human mesothelial cells af-
fects CA25 release [15], we found not effect with
patient age. We did however observe a relationship be-
tween serum and peritoneal CA125 concentrations. As
such some of the CA125 measured in the peritoneal
dialysate effluent may have come from the systemic
circulation.
We did not find any differences in peritoneal CA125
effluent concentrations and the cause of peritonitis, with
similar results obtained from patients with Gram + ve,
Gram-ve, fungal and polymicrobial infections. Similarly
there were no differences in peritoneal effluent CA125effluent of 4 hour 13.6 g/dl dextrose peritoneal dialysate
ed on peritoneal dialysis at 3 and 6 months (PD+), died
hs PD- 6 months PD+ 6 months PD-
0) 35 (23-64) 40 (11-82)
123) 49 (20-75) 52 (33-108)
100) 30 (15-46) 20 (14-100)
59) - 35 (18-59)
268) 31 (31-31) 25 (2-268)
terquartile range). All fungal infections resulted in catheter removal.
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peritoneal antibiotics and those who suffered treatment
failures. Although some studies have reported increased
peritoneal dialysate effluent WBC on presentation asso-
ciated with treatment failure [9], this has not been a uni-
versal finding [10,11]. Indeed studies using a disease
severity score, including microbacteriology results and
patient demographics could not show an association
with outcome [11]. As such our finding that peritoneal
dialysate effluent CA125 was not affected by the cause
of peritonitis and did not predict clinical outcome is not
untoward.
Whereas studies have suggested that repeated episodes
of PD peritonitis lead to an increased intra-peritoneal in-
flammatory response and increased risk of catheter re-
moval [16,17], we did not observe any increase in
peritoneal dialysate effluent CA125. Indeed, if anything
effluent CA125 concentrations tended to decline with
increasing number of infections, probably due to the
confounding effect of increasing dialysis vintage.
Our study does not appear to confirm the results of
the smaller earlier studies that effluent CA125 concen-
trations may have had a prognostic role in PD peritonitis
[6], as effluent peritoneal CA125 concentrations follow-
ing a 4 hour dwell were not significantly different ac-
cording to clinical outcomes. Peritoneal CA125 as a
prognostic indicator may lack sensitivity and specificity,
as increased peritoneal concentrations could be in-
creased due to reversible mesothelial cell injury, but also
secondary to mesothelial cell death and shedding [18].
As such peritoneal CA125 cannot differentiate between
reversible and irreversible mesothelial cell damage and
as such have limited association with clinical outcomes.
In addition systemic CA125 could add to local periton-
eal CA125 during active peritoneal inflammation. Stud-
ies which have serial measured PD effluent CA125 have
described a later second peak in PD CA125 concentra-
tions between 4 and 6 days post peritonitis presentation
suggesting peritoneal repair with mesothelial cell regen-
eration [6].
Conclusions
Despite some 30 years since the original studies report-
ing peritoneal CA125 as a biomarker of peritoneal mem-
brane integrity in peritoneal dialysis patients, a solid
understanding of the biologic significance of peritoneal
CA125 remains to be elucidated, and many questions re-
main unanswered [19]. We did not find any additional
diagnostic or prognostic benefit for measuring effluent
CA125 in PD patients presenting with acute peritonitis
compared to standard investigations, including periton-
eal white blood cell count and serum CRP. As such we
would not recommend the routine measurement of peri-
toneal CA125 during episodes of peritonitis.Abbreviations
CA125: Cancer antigen 125; CRP: C reactive protein; NHS: National Health
Service; PD: Peritoneal dialysis; WBC: White blood cells; UK: United Kingdom.
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